Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR

Clinical Pharmacokinetics
Shringi SharmaHao Xiong

Abstract

ABT-806 is a veneered 'humanized' recombinant IgG1κ antibody that is specific for a unique epitope of human epidermal growth factor receptor (EGFR) expressed only on tumor cells with the EGFRde2-7 (EGFRvIII) deletion mutant as well as tumors with wild-type amplified receptors. We aimed to develop a population pharmacokinetic model of ABT-806 in cancer patients, and to evaluate fixed versus body weight-based dosing regimens. The pharmacokinetics of ABT-806 were evaluated in a phase I, open-label study in cancer patients following intravenous infusion of ABT-806 every other week. A total of 587 serum concentrations of ABT-806 from 61 patients were analyzed using non-linear mixed-effects modeling. The impact of body weight-based and fixed dosing of ABT-806 was evaluated using a simulation approach. A two-compartment model with linear elimination was used to describe the serum concentration-time data of ABT-806. The population estimates of the apparent clearance from the central (CLc) and peripheral (CLp) compartments were 0.011 and 0.025 L/h, respectively. The apparent volume of distribution estimates of the central (V 1) and peripheral (V 2) compartments were 3.5 and 3.3 L, respectively. The estimates of inter-subject variability...Continue Reading

References

Oct 27, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antoinette R TanEric H Rubin
Feb 28, 2007·Critical Reviews in Oncology/hematology·Olivier DassonvilleGerard Milano
May 20, 2009·Targeted Oncology·Tianhong Li, Roman Perez-Soler
Jul 22, 2009·Journal of Clinical Pharmacology·Diane D WangKourosh Parivar
Sep 17, 2009·European Journal of Clinical Pharmacology·Adedigbo A FasanmadeHonghui Zhou
Sep 8, 2010·Clinical Pharmacokinetics·Nathanael L Dirks, Bernd Meibohm
Jan 20, 2012·Clinical Pharmacokinetics·Shuang BaiMark J Dresser

❮ Previous
Next ❯

Citations

Jan 7, 2020·Médecine sciences : M/S·David Ternant, Stéphanie Chhun
Feb 6, 2016·Molecular Cancer Therapeutics·Andrew C PhillipsEdward B Reilly

❮ Previous
Next ❯

Related Concepts

Related Feeds